DUBLIN, March 18, 2020 /PRNewswire/ -- Allergan plc
(NYSE: AGN) today announced that its Board of Directors has
declared a cash dividend of $0.74 per
ordinary share for the second quarter of 2020. The dividend will be
paid on the closing date of AbbVie's pending acquisition of
Allergan, which remains subject to regulatory approval and
customary closing conditions, or on June 15,
2020 if closing has not yet occurred. Allergan's second
quarter 2020 dividend will be paid to shareholders of record at the
close of business on April 16,
2020.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical
leader focused on developing, manufacturing and commercializing
branded pharmaceutical, device, biologic, surgical and regenerative
medicine products for patients around the world. Allergan markets a
portfolio of leading brands and best-in-class products primarily
focused on four key therapeutic areas including medical aesthetics,
eye care, central nervous system and gastroenterology. As part of
its approach to delivering innovation for better patient care,
Allergan has built one of the broadest pharmaceutical and device
research and development pipelines in the industry.
With colleagues and commercial operations located in
approximately 100 countries, Allergan is committed to working with
physicians, healthcare providers and patients to deliver innovative
and meaningful treatments that help people around the world live
longer, healthier lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; risks associated
with divestitures, acquisitions, mergers and joint ventures; risks
related to impairments; uncertainty associated with financial
projections, projected cost reductions, projected debt reduction,
projected synergies, restructurings, increased costs, and adverse
tax consequences; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2019.
Except as expressly required by law, Allergan disclaims any intent
or obligation to update these forward-looking statements.
CONTACTS:
|
Allergan:
|
|
Investors:
|
|
Manisha Narasimhan,
PhD
|
|
(862)
261-7488
|
|
|
|
Media:
|
|
Lisa Brown
|
|
(862)
261-7320
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/allergan-declares-second-quarter-2020-cash-dividend-of-0-74-per-ordinary-share-301025863.html
SOURCE Allergan plc